Cancer drug that targets two immune-evading tumor tactics performs well in early clinical trial

by

A “two-for-one” cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scientists from UPMC Hillman Cancer Center who led an international, early-phase clinical trial report in the journal Nature Medicine.

Leave A Comment

Your email address will not be published. Required fields are marked *